Novartis Investigative Site

San Daniele del Friuli, UD 33038

0 studies enrolling now · 9 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease, Chronic Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Hypertension, Type 2 Diabetes Mellitus

Studies at this site

• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction — Completed
• Efficacy and Safety of LCZ696A in Patients With Essential Hypertension — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early